Clinical Trial Update: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the GD2-SADA:177Lu-DOTA complex in GD2-expressing solid tumors is currently recruiting, including small cell lung cancer, mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Neuroblastoma
• Sarcoma
• Small Cell Lung Cancer

Drugs mentioned

• GD2-SADA:177Lu-DOTA Complex

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: SCLC, Malignant Melanoma | Phase 1 | Status: RECRUITING